Data I/O Corp

This management proposal requests shareholder approval to increase the number of shares available under Data I/O’s 2023 Omnibus Incentive Compensation Plan by 2,000,000 shares (bringing the total authorized under the Plan to 2,500,000 plus any unused prior-plan shares and adjustments). Management argues the increase is necessary to preserve the company’s ability to grant equity awards—options, RSUs, PSUs and other awards—that are core components of executive and employee compensation used to attract, retain and motivate personnel and align their interests with shareholders. The Compensation Committee and Board frame the request as a multi-year planning decision intended to provide flexibility for future hiring, retention and potential transactions (e.g., acquisitions) that may require equity consideration, while acknowledging possible dilution. The proposal includes customary protective features: limits on annual awards per participant, no repricing without shareholder approval, limited recycling of shares, minimum vesting, and clawback subject to company policies. Approval requires a majority of votes cast; abstentions and broker non‑votes are not counted. From a governance perspective, the requested 2,000,000-share increase is material relative to the company’s ~9.39 million shares outstanding as of the record date and should be evaluated against historical burn rate (three-year average ~3.69%) and the company’s stated near-term grant needs. Analysts should weigh the potential dilution against the need to incentivize management and employees in a smaller‑cap company where equity is a key retention tool; the Board’s recommendation and the company’s explicit rationale reduce uncertainty but investors should monitor projected grant pacing, potential acceleration on change in control, and insider participation in future grants. If approved, the Company will be able to continue its current equity compensation practices without turning to cash or alternative retention tools, but shareholders will face incremental dilution and should expect future disclosures on usage and burn rate to assess long-term impact.

This management proposal asks shareholders to approve issuing shares in excess of the Investors Issuance Cap (approximately 19.99% of outstanding shares) to two institutional investors under a May 14, 2026 Securities Purchase Agreement that includes common shares, a convertible note, and warrants for an aggregate $9 million financing. Nasdaq rules require shareholder approval when issuance could equal 20% or more of outstanding shares at a price below the Nasdaq minimum or could result in a change of control; management seeks this approval to allow conversion/exercise of the convertible securities rather than forcing cash repayment of the Note once issuance caps are reached. The Convertible Securities include a five‑year note convertible into Series B non‑voting preferred stock (initial conversion price implied into common at $2.50), warrants exercisable at $3.00 for five years, and initial common share issuance; conversion mechanics, ownership caps (9.99% per investor) and an Investor Issuance Cap of 1,869,470 shares are included to limit immediate concentration. Management frames the approval as necessary to preserve liquidity flexibility and to avoid potential cash strain at maturity; the board also emphasizes compliance with Nasdaq Listing Rules 5635(b) and (d). For investors, material considerations are dilution risk (possible issuance of up to ~2.73 million common shares upon full conversion of the Note alone before ownership caps), price adjustments on recapitalization events, and the potential for an investor to hold 20%+ post-issuance, which could be treated as a change of control under Nasdaq guidance. If shareholders refuse the approval, remaining principal would need to be repaid in cash upon reaching the Issuance Cap, potentially straining the company’s liquidity and hampering its ability to raise capital; if approved, shareholders will face dilution but the company gains financing and conversion flexibility. Analysts should evaluate the transaction’s pro forma capitalization, anti‑dilution protections, conversion mechanics, investor identity and stated investment rationale, the company’s cash runway without this financing, and whether management’s disclosure of alternative financing options and use of proceeds sufficiently mitigates dilution concerns.

This is an advisory (non-binding) shareholder vote to approve the company’s named executive officer compensation as disclosed in the proxy, including the 2025 Summary Compensation Table and narrative disclosure. Management presents a pay-for-performance framework combining base salary, an annual incentive (MICP) tied to financial performance metrics (historically EBITDA and revenue growth), and long-term equity awards (options, RSUs, PSUs) designed to align management incentives with shareholder value and retention needs. The Board highlights features intended to limit excessive risk-taking: capped MICP payout (0–200% of target), multi-year PSU performance metrics, multi-year vesting schedules, clawback policy, and limits on repricing of options. Given the company’s recent financial results and the historical shareholder support (92.6% approval in 2025), the Board will consider the advisory vote outcome when setting future compensation but is not bound by it. Investors should evaluate whether the disclosed targets, realized payouts, and equity grant pacing adequately tie pay to sustained improvements in profitability and TSR, and whether governance safeguards (clawbacks, committee oversight, burn-rate monitoring) sufficiently mitigate dilution and alignment concerns. The advisory nature means the vote is a signal rather than a mandate; a strong dissent would typically trigger more significant Board engagement and potential compensation design changes, whereas strong support validates current program design.